Category: Pfizer
-
Federal Circuit upholds decision to throw out $107.5M patent infringement verdict against AstraZeneca
The precedential decision, confirming the invalidation of two of Pfizer subsidiary Wyeth’s cancer drug-related patents, held that the plaintiff not only failed to rebut evidence on certain issues, but its own experts agreed against it.
-
UPC Munich LD revokes Promosome’s mRNA patent, dismisses infringement claims against BioNTech, Pfizer over Comirnaty
The UPC’s Munich LD revoked Promosome’s mRNA patent as invalid over prior art and found no infringement by BioNTech and Pfizer’s Comirnaty vaccine, ending the dispute.
-
Pfizer settles with three Vyndamax generic challengers mid-trial, extends exclusivity, presumably through pay-for-delay
Pfizer has quickly reached a settlement with Cipla, Hikma, and Dexcel during a five-day bench trial in Delaware, ending the dispute and extending its effective monopoly.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technologyÂ
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
Federal Circuit tosses Pfizer’s $42M+8% verdict against Daiichi, AstraZeneca: claiming 81 combinations out of gazillions described defeats disclosure, enablement
In a precedential opinion, the central U.S. appeals court for patent rulings overturns a Texas jury verdict given the discrepancy between a broad description and a specific claim term.
-
Pharma patent litigation updates: Boehringer, Orion, Pfizer, Kaleo file fresh patent infringement suits in District of Delaware
The District of Delaware continues to receive a substantial volume of pharmaceutical patent infringement complaints, with an arthritis-related Pfizer suit and diabetes-related Boehringer suit among the latest.
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation actionÂ
The move does not come as a major surprise, given the pharma companies’ previous success against GlaxoSmithKline in the UK.
-
BREAKING: GSK cashes in on license deal as CureVac settles U.S. patent dispute with acquirer BioNTech and Pfizer for $790M+
Pfizer and BioNTech have settled their three-year COVID vaccine-related patent infringement dispute with CureVac in the U.S., granting the latter and its licensing partner GSK $370 million each.